Abstract We previously reported a loss of cholinergic neurons within the pedunculopontine tegmental nucleus (PPTg) in rats that had been intra-nigrally lesioned with the proteasomal inhibitor lactacystin, with levels of neuronal loss corresponding to that seen in the post-mortem pedunculopontine nucleus (PPN) of advanced Parkinson's disease (PD) patients. Here we reveal lower expression values of the acetylcholine synthesising enzyme, choline acetyltransferase, within the remaining PPTg cholinergic neurons of lesioned rats compared to sham controls. We further characterise this animal model entailing dopaminergic-and non-dopaminergic neurodegeneration by reporting on stereological counts of non-cholinergic neurons, to determine whether the toxin is neuro-type specific. Cell counts between lesioned and sham-lesioned rats were analysed in terms of the topological distribution pattern across the rostro-caudal extent of the PPTg. The study also reports somatic hypotrophy in the remaining non-cholinergic neurons, particularly on the side closest to the nigral lesion. The cytotoxicity affecting the PPTg in this rat model of PD involves overexpression and accumulation of alpha-synuclein (aSYN), affecting cholinergic and noncholinergic neurons as well as microglia on the lesioned hemispheric side. We ascertained that microglia within the PPTg become fully activated due to the extensive neuronal damage and neuronal death resulting from a lactacystin nigral lesion, displaying a distinct rostro-caudal distribution profile which correlates with PPTg neuronal loss, with the added implication that lactacystin-induced aSYN aggregation might trigger neuronophagia for promoting PPTg cell loss. The data provide critical insights into the mechanisms underlying the lactacystin rat model of PD, for studying the PPTg in health and when modelling neurodegenerative disease.
Introduction
The human pedunculopontine nucleus (PPN) is located within the caudal pontomesencephalic tegmentum of the brainstem (Olszewski and Baxter 1982) and consists of an ensemble of cholinergic (originally identified by Mesulam et al. (1983) as cholinergic cell group Ch5) and noncholinergic neurons (reviewed in Martinez-Gonzalez et al. 2011) . The nucleus forms a functional component of the rostral locomotor region, which plays a central role in initiating and maintaining gait (Moro et al. 2010) , whilst forming associations during motor-response learning (Bortolanza et al. 2010) . In addition, the PPN fulfils a key role in maintaining intact vibrissal sensorimotor integration, required for guiding the behaviour essential for the animal's survival (Beak et al. 2010) . Several studies also implicated the PPN in cognitive processes, including attention, learning (Faure et al. 2014 ) and working memory (Taylor et al. 2004) . Moreover, as a critical component of the reticular activating system, the PPN is involved in regulating arousal and sleep-wake transitions (Hobson and Pace-Schott 2002; Datta and Siwek 2002) . Additional physiological roles may include controlling aspects of respiration and cardiovascular function (Topchiy et al. 2010) . Ongoing work aims to establish the precise neuronal substrate underlying the diverse functions associated with the PPN.
The importance of the PPN in neurodegenerative diseases such as Parkinson's disease (PD) was revealed by the reported loss of non-dopaminergic neurons in the PPNs of patients with PD (Hirsch et al. 1987; Rinne et al. 2008; Pienaar et al. 2013) and in patients diagnosed with the PDrelated disorder, progressive supranuclear palsy (Hirsch et al. 1987; Zweig et al. 1987; Dugger et al. 2012) . Such neuronal loss seemed to correlate positively with the severity of non-motor symptoms displayed by patients, including depression, constipation, pain, genitourinary problems and sleep disorders (Ahlskog 2005; Benarroch 1999 ). Although PD is currently without cure, the PPN has recently emerged as a potentially important therapeutic target for delivering deep-brain stimulation (DBS) therapy, as a means for alleviating aspects of PD symptoms in patients refractory to dopamine (DA)-replacement therapy (Jenkinson et al. 2005; Plaha and Gill 2005; Mazzone et al. 2005; Moro et al. 2010) . However, the neuronal substrate underlying these observed clinical benefits remains obscure.
Although the cholinergic cell population of the PPN (Ch5) remains the best described cell group, this only accounts for *50 % of all neurons present in both the human and rat PPN (Mesulam et al. 1983; Manaye et al. 1999; Mena-Segovia et al. 2009 ). Other non-cholinergic cell groups identified within the cholinergically defined border of the PPTg include glutamatergic (Clements and Grant 1990; Charara et al. 1996) , gamma-aminobutyric acid (GABA)ergic (Ford et al. 1995; Jia et al. 2003; MenaSegovia et al. 2009; Pienaar et al. 2013 ) and glycinergic ones (Fort et al. 1993; Mineff et al. 1998; Pienaar et al. 2013) , while PPN neurons that co-express two or more neurotransmitters have also been described (Lavoie and Parent 1994; Jia et al. 2003) . Although the location of the Ch5 cholinergic population is traditionally used to delineate the boundaries of the PPN (Mesulam et al. 1983; Mena-Segovia et al. 2009; Pienaar and Van de Berg 2013) , little is known regarding the other cell types and whether their cell bodies contribute to the PPN's boundary as clearly as the cholinergic neurons.
Here we provide further clinical validation of a rodent model of PD-related neurodegeneration, proposed previously (Vernon et al. 2010; Pienaar et al. 2015a) , involving the stereotaxic injection of the irreversible biquitin proteasomal system (UPS) inhibitor, lactacystin, into the substantia nigra pars compacta (SNpc), to impact on the cholinergic neurons of the pedunculopontine tegmental (PPTg) nucleus, the rodent equivalent of the human PPN (Paxinos and Watson 2009; Saryyeya et al. 2011) . We determined the expression levels of choline acetyltransferase, the enzyme for synthesising acetylcholine (ACh), in the remaining PPTg cholinergic neurons in lesioned versus sham-lesioned rats. In addition, we determined stereological cell counts and somatic area sizes of non-cholinergic neurons within the cholinergically defined PPTg. Topographical immunophenotype differences seen in the PPTg of this model of PD, suggested that microglia became activated as a result of neuronal damage and death. Additional assessment was undertaken from immunofluorescently stained PPTg slides, to ascertain if lactacystin induces overexpression and accumulation of alpha-synuclein (aSYN) within and in the vicinity of noncholinergic neurons and microglia that present with an activated phenotype.
Materials and methods Animals
Adult, male Sprague-Dawley rats, weighing 240-260 g (Charles River, UK) were utilised for this study. The rats were housed 2-3 animals per cage in a temperature-controlled environment (21°C). A 12-h-on, 12-h-off day/night cycle was maintained in the room where the animals were kept. Food and water was available ad libitum throughout. Imperial College London's ethics review panel approved all experimental protocols. All animal experiments were performed in accordance with the Animals (Scientific Procedures) Act, 1986 (UK).
Unilateral lactacystin lesions
Anaesthetised rats were stereotaxically lesioned by infusing lactacystin unihemispherically into the SNpc, as previously described (Pienaar et al. 2015a ). In brief, anaesthesia was initiated in the rats with 5 % Isoflurane (IsoFlo Ò , Abbot Laboratories Ltd., UK), vaporised into O 2 and delivered at a rate of 2 L/min. Anaesthesia was maintained with the flow rate set at 1.5 L/min. The animals' head was placed in a stereotaxic frame (Kopf 900, David Kopf Instruments, Tujunga, CA, USA), which was secured by hooking the incisors over the incisor bar and fitting non-traumatic ear bars into the ear canals and tightening the nose-clamp. The rat's ventral surface was placed on a thermostatically controlled electric thermal mat. Lacrilube (Allergan, UK) was placed on the rat's eyes to prevent dehydration. The head hair was then shaved, povidone-iodine topical antiseptic was applied topically to the scalp and Buprenorphine (Alstoe Animal Health, York, UK) and Bupivacaine (Taro, Ireland) was injected locally into the scalp, to provide analgesia and local anaesthesia, respectively. The skull was exposed by making a midline incision of the scalp. A small burr hole was drilled through the cranium over the left SNpc with a dental drill. In relation to bregma, identified as the intersection of the coronal and sagittal sutures, the SNpc's coordinates were: -5.2 mm (anterior-posterior) and ?2.4 mm (medio-lateral), similar to what was used previously (Vernon et al. 2010; Pienaar et al. 2015a) . A total of 4 ll lactacystin solution (2.5 lg dissolved in sterile saline, lactacystin was purchased from Enzo Life Sciences, UK), giving a total of 10 lg, was delivered into the left SNpc of 6 rats. The dose used here was similar to that used in several previous studies (Vernon et al. 2010; MacKey et al. 2013; Pienaar et al. 2015a ). The needle tip of a 10 ll Hamilton syringe was lowered to -7.6 mm (ventral-dural), relative to the dural surface of the brain. The toxin solution was then delivered at a rate of 1 ll/min. Sham-lesioned rats (n = 6) received an equal volume of sterile saline only. After delivering the toxin/toxin vehicle, the needle was left in situ for an additional 5 min to avoid efflux of the toxin, before it was slowly retracted from the brain. Glucosaline (5 ml of 0.18 % NaCl, 4 % glucose; Baxter Health science Ltd., UK) fluid replacement was administered intraperitoneally (i.p.) immediately following surgery. The scalp incision was closed with 4-0 monofilament nylon suture (Ethicon, Somerville, NJ) and the wound coated with povidoneiodine solution. Rats were left to recover in a heated recovery chamber and fluids were replaced by providing them with glucosaline (5 ml of 0.18 % NaCl, 4 % glucose; Baxter Health science Ltd. UK) intraperitoneally (i.p.).
Behavioural assessment
Amphetamine-induced rotational behaviour was observed at 14 days post-lesioning surgery, confirming accurate lesioning of the SNpc. Rotational asymmetry occurs due to a difference in DA levels between the two hemispheres, producing rotations away from the side with greater dopaminergic signalling, usually the unlesioned side. In sham-lesioned rats, no rotation was observed. D-Amphetamine (5 mg/kg, Sigma-Aldrich, Gillingham, Dorset, UK) was administered to the rats at a dose of 1 ml/kg i.p. At 30 min after drug administration, animals were left in a Perspex circling bowl (height 360 mm, diameter 400 mm) and the complete number of contralateral and ipsilateral turns was later calculated in 6 consecutive 5 min time-bins. Behaviour tests were recorded digitally and analysed later from a computer monitor by two evaluators, blind to experimental treatment.
Tissue collection and -preparation
At 5 weeks following the surgery, the animals were deeply anaesthetised with pentobarbital (100 mg/kg, i.p.) and Brain Struct Funct (2016 ) 221:2319 -2341 2321 perfused intracardially with saline, followed by cold 4 % paraformaldehyde in 0.1 M phosphate buffered saline (PBS). The brain was rapidly removed from the skull, immersed for 12 h in the same 4 % paraformaldehyde fixative at 4°C and then cryopreserved in 20 and then 30 % sucrose in PBS for 48 h at 4°C until descending to the bottom of the vial. Brains were then snap-frozen in isopentane and stored at -80°C until sectioning. Coronal, serial sections were cut through the SNpc at 20 lm thickness on a cryostat (Bright Instrument Co. Ltd., UK) at between -18 and -22°C, with each section transferred onto super-frosted glass slides. The sections were stored at -80°C until immunohistochemistry (IHC) was performed.
Single-antigen IHC Dopaminergic neurons, cholinergic and OX-42-immunoreactive (ir) neurons were labelled in separate brain sections containing either the SNpc (for staining dopaminergic neurons) or the PPTg (for staining cholinergic neurons or OX-42-ir cells). The OX-42 antibody serves as a microglia activation marker, by recognising the leukocyte integrin complement receptor type 3 receptor (CR3), also called the cluster of differentiation 11b (CD11b) receptor that is expressed by rat and mouse microglia (Graeber et al. 1989) .
In brief, the tissue sections were dried out overnight at room temperature (RT) and cleared in xylene (2 9 5 min; Sigma-Aldrich), before they were hydrated through a descending series of diluted ethanols (EtOH, 2 9 100, 90, 70, 50 %) and then washed well in water. Endogenous peroxidase was quenched for 20 min using 0.3 % H 2 O 2 . The sections were permeabilised with PBS containing 0.3 % Triton X-100 (PBST) for 15 min and then incubated with a blocking solution for 60 min at RT. This consisted of 5 % normal goat serum for sections immunoreacting to the DA biosynthesising enzyme, tyrosine hydroxylase (TH) and 5 % normal horse serum (NHS) for both the ChAT and OX-42 immunoreaction. The blocking solution was removed, before applying the primary antibody solutions to stain for TH (1:100, polyclonal rabbit, AB152, Millipore, Watford, UK); ChAT (1:100, polyclonal goat, P40101-0, Pel-freeze, Rogers, AR, USA) and OX-42 (1:1000, monoclonal mouse anti-rat, MCA275G, Serotec, Raleigh, NC, USA), overnight at 4°C. The next morning the sections were washed several times with PBS, after which they were incubated for 2 h at RT in their respective biotinylated secondary antibody (using goat anti-rabbit to label TH-ir neurons, horse anti-goat to label ChAT-ir neurons and horse anti-mouse for labelling OX-42-ir neurons, all purchased from Vector laboratories, Cambridge, UK), diluted in PBST at 1:200 each. This was followed by washing sections several times in PBS and then incubating for 60 min with the avidin-biotin peroxidase enzyme complex (ABC Elite, Vector laboratories), before visualising immunoreactivity by applying 3,3 0 -diaminobenzidine (DAB; Vector laboratories). Following incubation (3-5 min for TH, 8 min for ChAT and 10 min for OX-42), sections were washed thoroughly under distilled water, before submerging the slides in cresyl fast violet (CFV) for 5 min to counterstain the nissl bodies of all neurons. Slides were washed in distilled water and then dehydrated in ascending concentrations of EtOH, before clearing in xylene and applying a glass cover slip to each section, which was secured with di-n-butyl-phthalate-xylene (DPX, SigmaAldrich) mounting medium.
Double-antigen IHC
Using a combination of two chromogens, sections were double stained to co-identify on the same section, cholinergic-and all neurons (consisting of cholinergic and noncholinergic), by visualising antigen-targeting antibodies serially. PPTg-containing sections were deparaffinized, hydrated and endogenous peroxidase activity blocked as described above, followed by incubation in a blocking solution (5 % NHS, diluted in PBST) for 60 min at RT. The blocking solution was removed, before application of the primary antibody against ChAT (1:100, polyclonal goat, AB144P, Millipore), left overnight at RT. The next day, the sections were washed with PBS (3 9 5 min), before applying the secondary antibody (1:200, biotinylated horse anti-goat, Vector Biolabs, CA, USA) for 2 h at RT. The sections were washed with PBS again (3 9 5 min), after which the sections were incubated with ABC (ABC Elite kit, Vector Labs) for 30 min at RT. For visualising the reaction product, DAB (Vector Labs) was used as the chromogen and nickel sulphate as an intensifying reagent (dark blue).
The sections were washed well under running distilled water, before applying a primary antibody for marking mature neurons, neuronal-specific nuclear (NeuN) protein (1:200, monoclonal mouse, MAM377, Chemicon International Inc., Temecula, CA, USA), overnight at RT. The following day, the sections were washed with PBS (3 9 5 min) and the secondary antibody applied (1:200, biotinylated horse anti-mouse, Vector Biolabs) for 2 h at RT, following by washing with PBS (3 9 5 min). The sections were again exposed to ABC (Vector Labs), with similar incubation conditions as before. The sections were then washed briefly, before detecting antibody binding with a standard DAB reaction, which turned the reaction product brown. The sections were taken through ascending concentrations of EtOH (50, 70, 90, 2 9 100), cleared in xylene (2 9 5 min), before mounting with coverslips using DPX mounting medium (Sigma-Aldrich).
All antibody and blocking dilutions were made in PBST buffer for both single-antigen and double-antigen IHC. For all immunohistochemical procedure, controls were prepared by incubating sections without either the first or second antibodies. In all these reactions, no residual reactivity was observed. Moreover, omission of one of the primary or secondary antibodies resulted in the staining for a particular antigen disappearing, but without having an effect on the pattern of reactivity for the other.
Double-antigen immunofluorescence staining
For triple immunofluorescence labelling, the sections were washed with PBS, quenched with 3 % H 2 O 2 and then blocked with 10 % normal donkey serum in PBS for 60 min at RT, for labelling ChAT-, NeuN-and aSYN-ir neurons on the same sections and ChAT-, aSYN and OX-42-ir on a different set of sections. Sections were then incubated overnight with polyclonal goat anti-ChAT antibody (1:100, AB144P, Millipore), monoclonal rabbit antiNeuN antibody (1:200, MABN140, Millipore) and mouse anti-aSYN (1:100, BD Transduction Laboratories, Lexington, KY, USA) at 4°C for the ChAT-NeuN-anti-aSYN reaction.
Under similar incubation conditions as for the ChAT-OX-42-aSYN reaction, a primary antibody cocktail was applied containing antibodies at the following dilutions: 1:100 for anti-ChAT (polyclonal goat, AB144P, Millipore), 1:1000, for anti-OX-42 (monoclonal mouse anti-rat, MCA275G, Serotec) and 1:100 for anti-aSYN (BD Transduction Laboratories). The next morning, after several washes in PBS, the sections were incubated with species-specific secondary antibodies conjugated with Alexa Fluor 350, 546 and 488 (1:200 each) for labelling ChAT-ir neurons blue, NeuN-ir neurons yellow and the aSYN immunoreaction cyan-green in the ChAT-NeuNaSYN stained sections. For the ChAT-ChAT-OX-42-aSYN reaction, we made use of secondary antibodies conjugated with Alexa Fluor 350, 555 and 488 (1:200 each), to label ChAT-ir neurons blue, OX-42-ir cells yellow-green and aSYN protein cyan-green. All secondary antibodies were purchased from Invitrogen/Molecular Probes (Eugene, OR, USA) and were applied to the sections for 2 h at RT. The sections were then washed several times with PBS before mounting in an aqueous mounting medium (Vectashield, Vector Laboratories, Burlingame, CA, USA).
Fluorescent confocal images were captured by taking scans, spaced 0.8 lm apart through the z-axis, using a Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems, Heidelberg, Germany). Post-capture, the images were processed using Adobe Photoshop software (v.7.0), by adjusting the levels of brightness and contrast, whilst images were merged automatically by using built-in functions available with Photoshop software.
Anatomical identification of the SNpc and PPTg
The two areas of interest (AOIs), comprising the SNpc and the PPTg were delineated under a low-magnification view (109 objective lens). The SNpc was defined based on anatomical landmarks, where a population of neurons containing clear cytoplasmic TH immunoreactivity formed a dense, darkly staining cell type (Healy-Stoffel et al. 2012) . We referred to the rat atlas (Paxinos and Watson 2009 ) and the published work of Carman et al. (1991) to differentiate the SNpc from the SN subnucleus [the substantia nigra pars reticulata (SNr)], the ventral tegmental area and the retrorubral area) (Oorschot 1996; Baquet et al. 2009; Paxinos and Watson 2009) .
On the other hand, the PPTg's outline was delineated on the ChAT-stained sections by recognising the Ch5 cholinergic neurons' characteristic wedge-like shape (Paxinos and Watson 2009; Mesulam et al. 1983; MenaSegovia et al. 2009 ). The PPTg's rostral border consisted of the SNr, from where the PPTg extended dorso-caudally towards the lateral tip of the superior cerebellar peduncle, at *60°angle from a vertical line (Mena-Segovia et al. 2009 ).
Anatomical guidelines were used to distinguish between the PPTg-Ch5 cholinergic group and the cholinergic cell group Ch6, consisting of the laterodorsal tegmental nucleus (LDTg), which lies dorsal and caudal to the neighbouring PPTg. The LDTg dorsally abuts the aquaduct, whereas its caudal end locates to between the locus coeruleus and the fourth ventricle (Maskos 2008; Paxinos and Watson 2009 ). In the PPTg, cholinergic neuronal counts were performed by identifying ChAT-ir neurons, revealed by DAB (brown) staining. In addition, PPTg ChAT-ir neurons presented with medium-to-large somata, their longest axis being 20-40 lm long. In accordance with others, we also recognised larger ChAT-ir neurons, with 3-6 primary dendrites, these being either of a fusiform, triangular or multipolar shape. Instead, medium-sized ChAT-ir neurons appeared round or oval, with only 2-3 dendrites, which were thinner than the larger cell-type (Rye et al. 1987; Ichinohe et al. 2000) . On the other hand, previous studies revealed that non-cholinergic PPTg neurons predominantly have a much smaller cell body (10-20 lm) than cholinergic neurons, although certain glutamatergics and GABAergics may be of a larger size; however, such neurons often co-express ACh (Clements and Grant 1990; Ichinohe et al. 2000; Jia et al. 2003) . By taking this into account, we assumed that PPTg ChAT-ir neurons had to meet two criteria to be considered cholinergic: expressing brown colour (DAB) precipitate and being larger ([20 lm) in somatic diameter. On the other hand, all neurons (cholinergic and non-cholinergic) were identified as expressing nickel-DAB (black) precipitate, by using the neuronal marker NeuN. Cholinergic NeuN-ir neurons were then distinguished from non-cholinergic ones by somatic cell size, with non-cholinergic NeuN-ir neurons being smaller (\20 lm) (Mena-Segovia et al. 2009 ).
For microglial stereological counts, the PPTg's border outlines taken from ChAT-ir sections were mapped onto digital image scans of the OX-42-ir slides (immediately adjacent to the cholinergically stained slides) using a 109 dry objective, by digitally drawing directly onto the images using Microsoft Office PowerPoint Ò 2010 software. Microglial cell aggregation (microgliosis) was then quantified by stereologically counting OX-42-ir cells within the cholinergically outlined PPTg.
Imaging system and stereological estimates
Primary stereological data on the SNpc and PPTg were obtained using a computer (Dell Inc., Microsoft Windows XP Professional) interfaced with a Nikon Eclipse E800 microscope, equipped with a JVC 3CCD camera and motorised LEP MAC 5000 XYZ stage controller. ImagePro (v.7, MediaCybernetics, UK) stereology software was used for estimating the number of TH-and ChAT-ir neurons and OX-42-ir cells in lesioned and non-lesioned brain hemispheres for lactacystin-and sham-lesioned control rats. Systematic random sampling using the fractionator method (West et al. 1991 ) was employed to make unbiased and precise estimates of the total number of cells within the respective AOIs. Selecting the first section where the SNpc or the PPTg began, a systematic subset of sections (every 7th section of the series) was used to estimate the cell number within each subvolume (7 sections thick).
Cholinergic, non-cholinergic and microglia counts were carried out using a 209 air objective lens (0.45 NA). Dehydration and immunohistological processing of the tissue resulted in shrinkage, causing all cells to be visible in one focal plane of the section, thereby removing the need for 3-dimensional cell counting within sections. Counting frames (160 9 140 lm 2 for neurons, 100 9 100 lm 2 for microglia) were superimposed over the respective region of interest (ROI) in a uniform, systematically random manner, to cover between 40 and 60 % of the area. The counting software created sampling areas which included appropriate 'acceptance' and 'forbidden' lines, where only the neurons falling within the sampling area or touching the acceptance lines were included in the count (Gundersen and Jensen 1987) . For every section counted, the total area of the ROI was measured in each hemisphere. This value was used for calculating the area sampling fraction [asf = (number of counting frames 9 area of counting frame)/total area of ROI] to determine the proportion of the sectional area investigated. Approximately 12-16 SNpccontaining sections and 9-10 PPTg-containing sections were counted per rat, to span the entire SNpc and PPN. The total number of cells within each subvolume (N) was calculated as follows: N = number of cells in ROI 9 (1/ssf) 9 (1/asf), where ssf is the serial sampling fraction, 1/7 representing every 7th section throughout the AOI. For every section included, the N value was counted and summed to determine the total cell number for the entire volume of the SNc and the PPTg in both hemispheres. The degree of cell loss in the lesioned hemisphere was calculated as a percentage of the total cell number of the unlesioned hemisphere.
The cell density (number of positively labelled cells/ mm 3 ) of ChAT-and OX-42-ir cells in each 20 lm segments of the PPTg was calculated. Cell density, instead of cell counts, was used to eliminate volume as a variable and allow comparisons between segments. The thickness of the each section following immunohistological processing was calculated by multiplying the ROI area by this thickness, yielding the volume of each section. This volume was then multiplied by N to give the total number of cells within each sectional volume. Lastly, these cell numbers were multiplied by 109 to reflect the cell density within a cubic millimetre.
For determining the precision of the stereological estimates used here, the inter-animal coefficient of the variation (CV) between sampling units (animals) was estimated according to the formula given by Gundersen and Jensen (1987, standard deviation/mean total cell number). Variability in estimates was generally low (Suppl. Table 1 ). Pilot studies were carried out to determine suitable counting frame and sampling grid dimensions for counting TH-ir neurons in the SNpc and ChAT-, non-ChAT NeuN-ir neurons and OX-42-ir microglia in the PPTg (rostro-caudally), with the grid size that was adapted to achieve an acceptable Gundersen coefficient of error (CE), with CE values providing a standardised estimate of the precision or reproducibility of the sampling method used. The CE of the SNpc and PPTg neuron and PPTg microglia number estimates per rat was calculated using the quadratic approximation formula (Gundersen and Jensen 1987) . This parameter was well under 5 % for all regions and cell types examined, substantially exceeding recommended stereological guidelines (Slomianka and West 2005 ) (Suppl. Table 1 ).
Phenotypic characterisation of OX-42-ir cells
Microglia undergo a graded morphological change, from being dormant in disease-free brains, characterised by ramified processes, small somas, to undergoing gradual de-ramification, seen in brains affected by CNS disease, where the number of processes and process length progressively retract until cells displays an amoeboid morphology (Colburn et al. 1997; Kettenmann et al. 2011 ). An article by Banati (2002) overviewed the in vivo use of carbon-11, (R)-PK11195, a radioligand marker of peripheral benzodiazepine binding sites that are expressed by activated microglia, alongside binding detection with positron emission tomography (PET). The author remarked that although this approach is not cell-specific, the detection method shows relative cellular selectivity for activated microglia, confined in an anatomically meaningful way to the primary sites of tissue pathology and secondarily in the remote projection areas of the injured neurons. In this regard, in vivo imaging studies (e.g. Maia et al. 2012; Gianetti et al. 2015) support the notion that microglial responses can be deemed accurate markers of disease location, progression, chronicity and recovery, the biological basis of which comprise tight coupling between neuronal activity and the functional state of microglia. Morrison and Filosa (2013) demonstrated the use of a semi-automated method, where confocal images were converted to a binary and then skeletonised using imaging software to quantitatively analyse microglia morphology in a murine model of transient focal ischemic stroke. In this work, the degree of branching complexity and process length constituted the principal morphological metrics by which microglia were categorised. In other work, Blackbeard et al. (2007) proposed a quantitative method to assess microglial ramification in fixed tissue or live cell imaging entailing a qualitative 4 point rating scale for resting, mild, moderate and intense activation. In the current study, we distinguished between such different phenotypes to determine whether one type is more susceptible to the lactacystin-induced lesion by adapting the original 4-point rating scale to develop a 3-point discrete scale which describes OX-42-ir microglia during resting, partially and fully activated states. The resting state of microglia was defined by a small, ramified cell body, multiple fine neuronal processes. Microglia during partially activated state was recognised by processes being less numerous, thicker and shorter, the cell body being swollen and defined by greater staining. On the other hand, microglia during a fully activated state was identified as having a large, unramified cell body similar to amoeboid morphology and retracted neuronal processes.
This referral system was compatible with our approach which used unbiased stereology, recognised as the bestpractice method for quantifying biological features in tissue sections (Schmitz and Hof 2005) , while the approach employed by Morrison and Filosa (2013) required the capturing of a very high number of digital images taken of individual microglia at high (609) magnification to achieve sufficient resolution for image analyses.
Calculation of non-cholinergic neuronal somatic diameter
ChAT-ir neurons were revealed by DAB (brown) staining, while NeuN-ir neurons were revealed by nickel-DAB (black) staining. ChAT-only neurons were distinguished from non-cholinergic neurons by taking into account published criteria on the respective cytoarchitecture assigned to PPTg cholinergic and non-cholinergic neurons. From these, ChAT-ir neurons are described as being medium to large in somatic size (diameter 17.2 ± 3.9 lm, range 10.5-27.1; Steininger et al. 1997) , being generally multipolar, fusiform or triangular in shape (Rye et al. 1987; Spann and Grofova 1992; Steininger et al. 1997 ). On the other hand, non-cholinergic PPTg neurons were discerned as being generally small to medium in size (diameter 13.1 ± 3.7 lm) and appearing elongated or ovoid (Spann and Grofova 1992; Steininger et al. 1997 ).
For the current analyses, only the somatic diameter (lm 2 ) of PPTg non-cholinergic neurons were calculated of lactacystin-lesioned versus sham-lesioned rats, with a distinction made between the two cerebral hemispheres. The histological slides double stained for NeuN and ChAT were viewed under a 209 ''dry'' objective lens using a Nikon Eclipse 50i microscope. Contiguous, slightly overlapping individual images of NeuN-ir neurons were captured using a QImaging QIACAM Fas 1394 camera mounted to the microscope. A single mosaic for each hemisphere on each slide was made by stitching the images together using Image-Pro Plus software (v.5.1), from which individual non-ChAT NeuN-ir neurons' somatic diameters were calculated. To do so, the longest axis of the cell soma in individual, well-defined neurons were drawn using the drawing tool available with ImageJ software (v.1.4, National Institutes of Health, Bethesda, MD). The mean diameter of the soma of each cell was calculated as the average of three measures. Cells overlapping and not clearly in focus were excluded from analyses.
Integrated optical density measurements
A densitometry measurement protocol was applied to measure the ChAT-integrated optical densities (IOD), thereby reflecting the ChAT expression levels in the PPTg of lactacystin-lesioned and control rats in the left lesioned and right non-injected cerebral hemispheres. Images were taken on a Nikon Eclipse 50i Turboscan microscope with a colour QIcam Fast 1394-digital CCD camera (12 bits; QImaging Corp.) using the Image Pro software (v.6.0) at 10x magnification. To maintain uniformity, all scanned images had identical exposure times and were collected under the same microscope settings. Using ImageJ software (v.1.4), the images were converted into eight-bit gray scale from the original red-green-blue (RGB) images for processing binary (black and white) colour information, representative of the DAB content. The PPTg, identified by means of the darkly stained ChAT-ir neuronal cells, was tightly outlined and measured for integrated density. The IODs are reported as arbitrary values of mean pixel density per selection area.
Statistical analyses
The densities of TH-ir neurons in the SNpc were compared using a two-way Analysis of Variance (ANOVA), which considered within-rat variability and treatment (lactacystin vs. sham). ChAT-and non-ChAT NeuN-ir neuronal densities in the PPTg of lactacystin-and sham-lesioned rats were compared using a similar analyses strategy, to examine the effects of treatment and incremental distances away from the SNpc (S1-10). This was followed by a Bonferroni post hoc correction to compare each PPTg section (S1-10) between the two animal groups. The same method was used for analysing the ChAT IOD, the noncholinergic somatic cell size data and for analysing each of the microglia cell states (resting, partially activated and fully activated). All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) software 19.0 (IBM SPSS statistics). Values are expressed as the mean values ± standard error of the mean (SEM). The threshold level of significance was set at P [ 0.05 for all analyses performed here. P-values were designated as: ***P \ 0.001, extremely significant; **P B 0.01, highly significant; *P B 0.05, significant and P [ 0.05, non-significant (n/s).
Results

Validation of the nigrostriatal lesion
In lesioned rats, the pattern of amphetamine-induced circling (154 ± 28 complete turns) occurred exclusively in an ipsiversive direction. No rotational behaviour was observed in sham-lesioned control animals. Stereological counts of TH-ir SNpc neurons were made of multiple sections of the SNpc from each of the six lactacystin-injected rats and six sham-injected rats. Analysis revealed no significant variability between individual rats within either group (P [ 0.05, n/s). Stereological cell counts of the total number of SNpc dopaminergic neurons (Fig. 1a, b) compared favourably between the two hemispheres in shamlesioned control rats (left hemispheric side: 11,506 ± 255.84 neurons, right hemispheric side: 11,486 ± 177.6 neurons, P [ 0.05, n/s), translating to an overall percentage cell difference of only 0.17 %. A similar comparison of neuronal numbers in the non-injected right hemispheric SNpc of lactacystin-lesioned (11,496 ± 224.6 neurons) and control rats (11,486 ± 177.6 neurons) also demonstrated no significant difference (P = 0.4, n/s).
However, an inter-group comparison of cell loss in the injected left hemispheres of lactacystin-lesioned (5,896 ± 120 neurons) and control rats (11,506 ± 255.84) revealed a highly significant loss of dopaminergic neurons in the SNpc (***P \ 0.0001; Fig. 1a, b) translating to a 48.8 % difference. Furthermore, an intra-group comparison of TH-ir neuronal counts in the toxin-injected left (5,896 ± 120 neurons) and non-injected right (11,486 ± 177.6 neurons) SNpc of lactacystin-injected rats revealed a highly significant loss of dopaminergic neurons (***P = 0.0001), translating to an interhemispheric percentage cell loss of 48.7 % (Fig. 1a, b) . This result correlates to a large extent with previously reported TH-ir neuronal loss in this rat model of PD (Pienaar et al. 2015b ).
c Fig. 1 a Representative photomicrograph sections of TH-stained rostral midbrain coronal sections shows the lactacystin-induced partial loss of the SNpc, SNr and ventral tegmental area's (VTA) midbrain dopaminergic cell groups, sustained ipsilateral to the stereotaxic infusion, compared to the sham-lesioned control animal where the TH-ir remained intact. In both lesioned and control rats, this cell loss was only prevalent on the ipsilateral side of the lesion, with no cell loss observed in the contralateral SNpc. The lactacystininduced cell loss was seen to be non-uniform throughout the SNpc. In this example shown of a lactacystin-lesioned rat, the section shows a region of the SNpc in close proximity to the placement of the needle for delivering the toxin, resulting in significantly greatly damage to the SNpc and surrounding areas than what was observed in sections placed further away from the direct lesion site. Images were taken with a 94/0.10 NA air objective, scale bar 100 lm. b Unbiased stereological cell counts using an optical fractionator probe revealed a significant (***P \ 0.0001) loss of TH-ir SNpc neurons in serial brain sections of rats (n = 6) that had received a single lactacystin microinjection into the SNpc, compared to sham-lesioned controls (n = 6). SNpc neuronal counts are expressed as percentage cell loss detected on the injected hemispheric side, relative to counts made on the non-injected hemispheric side in the same treatment group. Values are given as the mean ± SEM. c Stereological quantification of ChAT-ir PPTg neurons reveal cellular loss unihemispheric to the intra-nigral injection site in all lesioned rats (n = 6), which proved statistically extremely significant (***P \ 0.0001) compared to counts made in the PPTg on the sham-lesioned hemispheric side of control rats (n = 6). ChAT-ir neuronal counts between the PPTgs of both hemispheres for the control rats were similar. d Unbiased stereology reveals the typical topographical distribution pattern of ChAT-ir neurons in the PPTg. Testing for an effect by distance away from the SNpc revealed a pronounced effect (***P \ 0.0001) in both sham-and toxin-lesioned rats. Results of a section-by-section post hoc analysis are shown, with cell counts being lower throughout the PPTg in the lesioned rats. The column bars represent the mean ± -SEM (a, b). e Low-magnification photomicrographs of representative PPTgs in control and lesioned rats illustrate the maintained loss of cholinergic neurons across the rostro-caudal extent of the nucleus. Images were taken with a 910/0.3 NA air objective, scale bar 200 lm
Stereological cell counts and topological distribution profile of ChAT-ir neurons
Comparison of the total counts of PPTg ChAT-ir neurons on the left, injected cerebral hemispheric side in lactacystin-lesioned rats (1,764 ± 23) and sham-injected control ones (3,191 ± 96), revealed a significant loss of PPTg cholinergic neurons (***P [ 0.0001, Fig. 1c ) in the lesioned animals. This loss equated to approximately 55 % in the lactacystin-injected rats, in good agreement with previously reported findings (Pienaar et al. 2015a) .
Analyses of topographical distribution of ChAT-ir stereology data on the left, injected side, revealed a significant difference in the cell density data as the PPTg was transitioned from a rostral to a caudal direction (***P \ 0.0001, Fig. 1d, e) , with values in the lactacystinlesioned rats being consistently lower in all PPTg segments, compared to control rat values. A section-by section post hoc comparison between the two treatment groups (conducted by using a Bonferroni correction) revealed the cell density data in the lactacystin-injected rats to be significantly lower in the PPTg of the following sections: S2 (*P = 0.021), S3 (*P = 0.012) and S8 (*P = 0.048, Fig. 1d ).
Densitometric measurements
When comparing the ChAT IOD values of cholinergic neurons of the left, injected side of lactacystin-lesioned (1.59 9 106 ± 1.06 9 105) with the sham-lesioned rats (2.79 9 106 ± 2.01 9 105), a highly significant difference was found (***P [ 0.0001, Fig. 2a) . Analyses also revealed a highly significant effect due to distance away from the SNpc (***P [ 0.0001, Fig. 2b, c) . Compared to control rats, lactacystin-lesioned rats had lower IOD values at each section (S1-10) of the PPTg, with extremely significant differences seen between the two treatment groups for S4 (***P [ 0.0001), S5 (***P [ 0.0001) and S6 (***P [ 0.0001), with significant but less pronounced differences at S7 (*P = 0.033) and S8 (*P = 0.022, Fig. 2b) . A between-group comparison of the ChAT IOD values within PPTg cholinergic neurons of the unlesioned right hemispheric side, revealed no significant difference in IOD values (P = 0.92, n/s).
Stereological cell counts and topological distribution profile of non-ChAT NeuN-ir neurons
An overall comparison of the total stereological cell counts made of non-ChAT NeuN-ir neurons in the left hemispheric sided PPTg of the lactacystin-lesioned (12,268 ± 193 neurons) and sham-lesioned control rats (16,109 ± 377 neurons) revealed a significant neuronal loss (***P [ 0.0001, Fig. 3a) . Comparison of the sham-lesioned rats (16, 067 ± 235) with lactacystin-lesioned ones (15,932 ± 351), on the same, non-injected hemispheric side, revealed similar neuronal densities (P = 0.74, n/s). On the left, lesioned hemispheric side, where an extremely significant neuronal loss was seen in the lactacystin-lesioned animals, a strong rostral-caudal patterning was discerned (***P \ 0.0001, Fig. 3b, c) .
A section-by-section post hoc comparison between the two treatment groups revealed the cell density data in the lactacystin-injected rats to be significantly lower in the following sections: S1 (***P \ 0.0001), S2 (***P \ 0.0001), S3 (***P \ 0.0001), S7 (**P = 0.003), S10 (*P = 0.013, Fig. 3b ). Moreover, a highly significant interaction effect was seen (***P \ 0.0001, Fig. 3b) , reflecting a more pronounced effect by the toxin in the PPTg sections that lay closest to the intra-nigral toxin injection site.
Somatic diameter and topological distribution profile of PPTg non-cholinergic neurons
Examination of the cell diameter of non-ChAT NeuN-ir neurons in the PPTg found that on the right, non-lesioned side, no effect by 'treatment' could be discerned (Fig. 4a) . On the other hand, in the PPTg on the left, injected cerebral hemispheric side demonstrated a significant difference (***P [ 0.0001, Fig. 4a ) between the lactacystin-lesioned (16.9 ± 0.23) and sham-lesioned control rats (19.69 ± 0.32). In the left PPTg, there was a more pronounced effect of the toxin at the rostral end of the PPTg, nearest to the sight of stereotaxic injection (***P \ 0.0001, Fig. 4b ). Moreover, a pair-wise comparison of the different PPTg sections of sham-lesioned and toxin-lesioned rats revealed statistically significant differences for the following: S2 (**P = 0.004), S3 (***P \ 0.0001), S4 (***P \ 0.0001) and S6 (*P = 0.029, Fig. 4b ).
Stereological cell counts and topological distribution profile of OX-42-ir cells
Comparison of PPTg resting microglia cell density between the PPTg on the left hemispheric sides in the lactacystin-lesioned (56,886 ± 3,291 cells) and sham-injected animals (73,547 ± 1,475 cells) revealed a significant difference in resting microglia (***P [ 0.0001, Fig. 5ai, b) ; with the number of resting microglia being considerably lower in the lactacystin-lesioned rats. The untreated right hemispheres showed no significant difference between the two groups (lactacystin-lesioned: 70,914 ± 801 cells; sham-lesioned: 74,112 ± 1225 cells), although a trend was observed for a lower number of resting microglia in the unlesioned, right hemisphere of rats injected with lactacystin on the left hemispheric side (P = 0.07, n/s).
To determine the relationship between neuronal loss following unilateral lactacystin lesioning of the SNpc and the activation of glial cells in the PPTg, we also determined the topographical distribution of OX-42-ir cells along the Fig. 2 a Comparison of ChAT IOD values of ChAT-ir PPTg neurons between lactacystinand sham-lesioned rats, within the left, injected hemispheric side of revealed a highly significant difference (***P [ 0.0001). b IOD densitometric values of ChAT, measured in all PPTg segments (most rostral to most caudal), reveal lower IOD values in lesioned rats (n = 6) compared to sham ones (n = 6), with a significant effect seen for distance from the SNpc (***P \ 0.0001). A section-bysection comparison reveals significant differences for values obtained from lesioned rats compared to control animals. The column bars represent the mean ± SEM (a, b). c Representative photomicrograph images of ChAT-ir PPTg neurons in the lesioned and sham-lesioned hemispheres of control and lesioned rats demonstrate the decreased expression of ChAT in toxin-lesioned rats seen across the whole rostral-caudal extent of the PPTg. Images were taken with a 920/0.4 NA air objective, scale bar 25 lm rostro-caudal extent of the left, injected PPTg. On the lesioned, hemispheric side there was a highly significant decline in the number of resting microglia as distance increased away from the SNpc (S1-10), in both groups of rats, although the cell density per section of the PPTg was consistently lower in the lesioned rats (***P [ 0.0001, Fig. 5b ). Post hoc analysis revealed the following sections to have significant differences between the two groups of Fig. 3 a Comparison of the estimated total density of nonChAT NeuN-ir PPTg neurons within the left, injected side of lactacystin (n = 6) and shamlesioned (n = 6) rats revealed a highly significant difference in neuronal density (***P [ 0.0001). b Density distribution profile of such neurons in the left hemispheric PPTg revealed significant differences as the PPTg was transitioned rostral to caudal. A section-wise comparison shows that the most pronounced neuronal loss were in the rostral PPTg sections, with the significance levels following a Bonferroni correction that are shown. Values are shown as the mean ± SEM (a, b). The column bars represent the mean ± SEM (a, b). c Low magnification representative photomicrographs illustrate how loss of non-cholinergic neurons was exaggerated in the rostral portion of the PPTg, with cell loss that was maintained across the extent of the nucleus. Images were taken with a 94/ 0.10 NA air objective, scale bar 100 lm rats: S1 (**P = 0.006), S4 (*P = 0.016) and S7 (**P = 0.008, Fig. 5b) .
In lesioned rats, OX-42-ir cells acquired an amoeboid morphology with retracted, thickened processes and enlarged soma. The density of partially activated microglia cells between the injected, left hemispheres of the lactacystin-lesioned (14,444 ± 1467) and sham-lesioned rats (7,001 ± 466) was significantly higher in the lesioned animals (P [ 0.0001, Fig. 5c ). In contrast, in the untreated right hemisphere, no significant difference was seen in the density of this phenotypically categorised microglia between the two groups (lactacystin-lesioned: 7,722 ± 983; sham-lesioned: 7,022 ± 547; P = 0.37, n/s).
Analyses of the topological distribution of the partially activated microglia in the left PPTg revealed very high numbers of partially activated microglia in the PPTg sections closest to the sight of toxin injection (the SNpc) in the lactacystin-lesioned rats, resulting in a highly significant interaction effect between the factors treatment (sham vs. lactacystin) and distance away from the injection site (***P [ 0.0001). A section-by-section comparison between the two groups in the left hemispheric half showed the following significant differences (Fig. 5c ): S1 (***P \ 0.0001), S2 (***P \ 0.0001) and S5 (**P = 0.005).
Finally, comparison of the density of fully activated microglia between the left hemisphere of the lactacystinlesioned (18,281 ± 871) and sham-injected rats (212 ± 67) revealed the density to be far lower in the unlesioned rats (***P \ 0.0001, Fig. 5aiii, d) . In contrast to previous data, the untreated right hemisphere showed a significant difference (*P = 0.028) between the lactacystin-lesioned (265 ± 66) and sham-lesioned rats (171 ± 82), although this difference was not as pronounced as many of those observed in the left-hand hemisphere. Fig. 4 a Compared to control rats (n = 6), the mean somatic diameter of remaining nonChAT NeuN-ir neurons within the PPTg of lesioned rats (n = 6) revealed pronounced (***P \ 0.0001) shrinkage when measures were taken on the hemispheric side ipsilateral to the intra-nigral toxin injection site. b Variation in terms of average cell diameter was detected, in relation to distance from the site of stereotaxic injection (***P \ 0.0001). A section-wise comparison shows the shrinkage effect to be limited to the rostral part of the PPTg. Results of section-wise post hoc comparison are shown. The column bars represent the mean ± SEM The topological distribution profile for the left, lesioned PPTg revealed a highly significant decline in the number of activated microglia in lactacystin-lesioned animals, with a highly significant decline discerned in cell numbers relative to distance from the SNpc increased (***P \ 0.0001, Fig. 5d ), with cell count numbers in the control animals remaining almost unchanged. All pair-wise sectional comparisons were deemed highly significant (***P \ 0.0001); however, a highly significant interaction effect was discerned (***P \ 0.0001) with the greatest increase in the number of fully activated microglia that was seen in the most rostral PPTg sections.
The data raise the intriguing possibility that lactacystin may have induced microglial proliferation in the PPTg, in response to neuronal injury and/or inflammation. In light of previous work which showed lactacystin capable of augmenting protein levels of the proliferation-associated nuclear protein Ki-67 (Wu et al. 2000) , studies to assess the proliferative capacity of microglia, such as through stereological assessment of Ki67-ir microglia, promise to reveal significant information as to lactacystin's mechanism of effect and the role played by inhibition of the UPS in the inflammatory response seen in PD.
aSYN immunoreactivity
In previous work performed on human post-mortem tissue, aSYN-positive Lewy bodies and Lewy neurites in the PPN of PD cases, compared to the absence of aSYN pathology in all of the neurologically intact control cases was described (Pienaar et al. 2013) . Numerous studies revealed aSYN pathology in the SNpc of the lactacystin rat model of PD (Niu et al. 2009; Vernon et al. 2010; Lorenc-Koci et al. 2011; Pienaar et al. 2015a ). In the present study, immunofluorescence histochemistry revealed aggregated aSYN-ir aggregates which overlapped with PPTg cholinergic neurons in lesioned rats, but was absent in non-lesioned control rats (Fig. 6a, b) , similar to previous observations (Pienaar et al. 2015a) . aSYN labelling appeared as clusters within the ChAT-immunoreactive stained outlines of cholinergic neurons, indicating soluble aggregates. Related to this, aSYN-ir deposits have also been observed to accumulate in cholinergic neurons of the nucleus basalis magnocellularis following an intracerebral stereotaxic injection of lactacystin, which were concomitant with marked cholinergic deficits (MacInnes et al. 2008) . aSYN-ir deposits were also observed in noncholinergic PPTg neurons, but to a lesser extent than was seen for the PPTg cholinergics, with aSYN-ChAT overlap seen in all the PPTg sections examined for lesioned rats. However, the current report indicates that aSYN deposition might affect PPTg cholinergic neurons to a greater extent than non-cholinergic neurons. This increased vulnerability affecting PPN cholinergic neurons over non-cholinergic ones during PD or PD-like pathology is in line with previous work performed on PD-affected human post-mortem tissue (Pienaar et al. 2013) , which indicated that PPN GABAergic and glycinergic neurons compensate for the devastating impact suffered by PPN cholinergic neurons.
Within the cholinergically defined border of the PPTg, we also observed that unlike the absence of aSYN deposits seen in sham-lesioned controls (Fig. 6c) , aggregated aSYN immunoreactity was found within close proximity of type III (activated) microglia (Fig. 6d) , in line with the previous suggestion that aggregated aSYN can activate microglia (Zhang et al. 2005) .
Discussion
A major limitation in efforts to comprehend the functions of the PPN and how these are impacted upon during CNS diseases relates to the cellular diversity of the PPN region and to the clinically valid characteristics of experimental tools for studying the PPN during health and when affected by disease. In rats receiving an intra-nigral unilateral injection of the irreversible UPS inhibitor, lactacystin, we b Fig. 5 a Representative brightfield photomicrographs of serial rat brain sections containing the PPTg, stained immunohistochemically for OX-42-ir microglia. For stereological cell counts, such cells were distinguished between those that exhibited a morphological phenotype of resting, partially activated or fully activated microglia. i Resting microglia (white arrow heads), show small cell somas, along with multiple, fine dendritic processes. ii Compared to resting microglia, partially activated microglia (white arrow heads) was identified as having swollen somas and fewer, thicker and retracted processes. iii Fully activated microglia, (white arrow head) show large, intensely stained somas, but with few processes seen. In fact, in some instances no processes were seen for microglia placed in this category. Images were taken with a 920/0.4 NA air objective, scale bar 100 lm. b Treatment had a significant effect on resting OX-42-ir cells in the left, injected hemisphere (***P \ 0.0001), with lactacystin-treated animals (n = 6) showing a reduction in OX-42-ir cellular density when compared to sham controls (n = 6). The topographical distribution pattern of these cells was also significantly different across the different PPTg segments (***P \ 0.0001), with results of a post hoc pair-wise comparison shown. c Overall, treatment had a significant effect on partially activated OX-42-ir cells in the left hemisphere, but in the case of the partially activated microglia, numbers were higher in the left-hand hemisphere for the lactacystin-treated animals (***P \ 0.0001). The rostro-caudal topographical distribution pattern shows striking changes as the PPTg is transitioned, with significance levels following comparison of individual PPTg sections that are indicated on the graph, the strongest effect being seen in the rostral portion of the PPTg. d Treatment had a highly significant effect on fully activated OX-42-ir microglia in the left, injected hemisphere, with density numbers that were far higher in this hemisphere for the lactacystin-treated animals compared to controls (***P \ 0.0001). The topology reflected this with all the pair-wise difference between the sections of the two groups of rats having highly significant differences (***P \ 0.0001). The column bars represent the mean ± SEM (b, c, d) recently reported a loss of PPTg cholinergic neurons at 5 weeks post-lesion (Pienaar et al. 2015a) , with the level of cell loss correlating to that reported for post-mortem PPNs in advanced PD patients (Hirsch et al. 1987; Rinne et al. 2008; Pienaar et al. 2013 ). Compared to other toxin-based animal models of PD, the level of dopaminergic cell loss achieved in this model may be suboptimal for achieving profound behavioural effects and is likely to be below threshold for apomorphine-induced turning (Hudson et al. 1993) , although in the current study, amphetamine-induced turning was consistently achieved. In human PD the DA depletion is typically more severe when symptoms reliably appear, with severe DA loss that can be mimicked by lesioning with a toxin such as 6-hydroxydopamine (6-OHDA). In 6-OHDA-induced degeneration, the model can be altered to either mimic the early Fig. 6 a A representative fluorescent image showing the lack of aSYN depositions (green) of sham-lesioned control rats seen in the PPTg, containing ChAT-ir (blue), NeuN-ir (yellow) neurons. Overlaid neurons shown in the far-right panel shows PPTg cholinergic neurons, whilst yellow ones reveal non-cholinergic ones. b aSYN-ir cytoplasmic inclusions (green) were observed in lactacystin-lesioned PPTg ChAT-ir neurons (white arrows). Although expressed in far fewer non-cholinergic PPTg neurons than cholinergic ones (examples are shown of non-ChAT-ir neurons not containing aSYN-ir deposits, red arrowheads), aSYN-ir inclusions were also present in PPTg noncholinergic neurons (white arrowheads). c A representative example of the lack of aSYN immunoreactivity (green) seen in the PPTg, containing ChAT-ir neurons (blue), co-stained for OX-42 microglia (yellow) of a sham-lesioned control rat. d In contrast, in addition to strong aSYN immunoreactivity seen in the ChAT-ir neurons (blue), aSYN aggregates (green, white star) was discerned within close proximity of OX-42-ir cells conforming to a fully activated state, in lesioned rats, although aSYN depositions did not completely overlap with the activated microglia. Images were taken with a 940/1.30 NA oil-immersion objective, scale bar 25 lm presymptomatic or advanced symptomatic stages of the disease with a striatal lesion producing a moderate and protracted lesion over several weeks, while a medial forebrain bundle (MFB) lesion is severe and develops rapidly over 1-2 weeks. Injection of 6-OHDA into the SNpc causes anterograde degeneration of the nigrostriatal dopaminergic system, producing a loss of dopaminergic neurons in the SNpc and loss of dopaminergic terminals in the striatum (to which the SNpc projects to), similar to that observed in PD (Moses et al. 2008) . The intra-nigral lesioning model induces extensive DA neurodegeneration in the absence of the high mortality rate seen in MFB-lesioned animals. The current study unilaterally injected lactacystin into the SNpc, producing a loss of SNpc DA neurons slightly exceeding 50 % and therefore entails a less severe level of DA depletion which is more akin to presymptomatic or early signs of PD and is therefore arguably more likely to be amenable to the testing of beneficial treatments and viral vector mediated neuralspecific manipulation strategies such as optogenetics or designer receptors exclusively activated by designer drugs (DREADD) (Sharma and Pienaar 2014) , than a more severe DA loss affords, where few dopaminergic neurons remain for therapeutic targeting or viral vector neuronal transfections.
Here we also validated our previous finding that 35 % of PPTg neurons are lost on the hemispheric side which received the toxin injection (Pienaar et al. 2015a) , confirming that the nigral lesion impacts on the adjacently lying PPTg region and thereby provides a valid tool for studying neurodegenerative changes affecting the mammalian rostral brainstem. However, realisation is growing that noncholinergic PPN neuronal cell types may be fundamentally important in several PPN-modulated activities (Ros et al. 2010; Ye et al. 2010; Fogel et al. 2010) . Moreover, studies have begun to show that PPN non-cholinergic neurons are also affected during neurodegenerative diseases such as PD, but that PPN cholinergics appear more vulnerable to disease processes, such as the finding that a 23 % reduction of non-cholinergic neurons were seen in the PPNs of PD cases compared to controls, but with a 36 % reduction noted for PPN cholinergics (Rinne et al. 2008) . Our previous work (Pienaar et al. 2013) revealed that along with a pronounced loss of cholinergic neurons, further post-mortem pathological changes seen in the PPN of PD patients was a loss of neurons producing GABA and glycine as output, as well as altered somatic cell size that affected the remaining neurons of all neuronal subtypes studied. Interestingly, the study reported a significant upregulation of several mitochondrial proteins in GABAergic and glycinergic neurons, which contrasted with cholinergic neurons, which showed down-regulation of the same proteins. This suggests that in the PPN of PD patients, an imbalance exist in the activity of key neuronal subgroups of the PPN in PD, potentially due to abnormal inhibitory activity and altered cholinergic outflow, which was replicated in the lactacystin rat model of the human disease. Here we provide the first thorough quantitative measurement of how lactacystin lesioning affects the elaborate non-cholinergic neuronal network in the rat PPTg. We show that the model accurately reflects the PPTg non-cholinergic cell loss observed in post-mortem brains of PD patients, which likely contributes to the variance of motor and non-motor features that associate with parkinsonism (Pienaar et al. 2013) . Remaining non-cholinergic neurons displayed marked somatic shrinkage, with the impact that was seen to be greatest in the rostral portion of the PPTg, which lies closest to the intra-nigral site of toxin injection.
The current results open a new avenue of research to identify the specific functional role played by neuronal populations affected by lactacystin-mediated mechanisms, their interrelations and their neurochemical identity. In this regard, a distinction between neuronal types present in a highly heterogeneous nucleus such as the PPN, need to consider that PPN neurons can co-express dual major neurotransmitters within PPN neuronal somas, dendrites and axon terminals (Lavoie and Parent 1994; Jia et al. 2003) . However, contrasting findings have been reported by Wang and Morales (2009) , whose study failed to confirm the hypothesis that PPTg cholinergic neurons co-release ACh with either glutamate or GABA. Such contradictory results further highlight the need for investigations aimed at ascertaining the neurotransmitter identity of PPTg neurons, and how these are affected during toxin models that mimic aspects of neurodegenerative disease.
Additionally, conventional immunohistological targeting approaches do not provide accurate labelling of glutamatergic neurons, comprising one of the major neuronal types seen in the PPN (Clements and Grant 1990; Charara et al. 1996) , with in situ hybridization that currently provide the only option (Martinez-Gonzalez et al. 2012) . However, in situ hybridization detection methods is far from ideal, as they are vulnerable to showing false positives from non-specific binding, while only showing the presence of messenger RNA and without providing information about the level of protein translation, crucial for assessing the functional viability of neurons.
Lactacystin, which binds and inhibits specific catalytic subunits of the proteasome, may be involved in determining cell fate and morphology (Orlowski 1999) . The mechanism by which lactacystin induces apoptosis remains a topic of considerable investigation. Recent work found that lactacystin downregulates viability of a protein complex that controls transcription of DNA, nuclear factor kappa B, resulting in a killing effect on two gastric cancer cell lines (Li et al. 2014) . In other work, two key pathogenetic mechanisms underlying PD, mitochondrial dysfunction and aSYN accumulation, were linked in a common cell death pathway (Bir et al. 2014) . The study showed that in intact human neuroblastoma cells, lactacystin causes an accumulation of aSYN with concomitant mitochondrial dysfunction and cell death. Lactacystin-induced cell death was prevented by knocking down the aSYN gene, suggesting that intracellular accumulation of aSYN in cells following proteasomal inhibition leads to mitochondrial impairment and then cell death, the neurodegeneration which could be prevented by knocking down aSYN. In the present work, the cell loss affecting the PPTg in lesioned rats, on the lesioned hemispheric side, was concomitant with PD-related motor abnormalities and the presence of aSYN-ir cytoplasmic inclusions, which forms an additional pathological feature of PD (Spillantini et al. 1998) , in both cholinergic and non-cholinergic PPTg neurons, but with far less deposition noted in PPTg noncholinergics. Previous studies reported PD-related aSYN overexpression and aggregation in the SNpc neurons of rats lesioned with lactacystin (Niu et al. 2009; Vernon et al. 2010; Lorenc-Koci et al. 2011; Pienaar et al. 2015a) . Moreover, recently we were the first to report on the presence of punctuate aSYN staining within and surrounding some surviving PPTg cholinergic neurons, ipsilateral to the lactacystin microinfused SNpc (Pienaar et al. 2015a) . Although a study had previously shown aSYN-ir Lewy bodies and Lewy neurites to be present in the PPN of PD-affected post-mortem tissue (Pienaar et al. 2013 ), the neuronal types in which these pathological changes occurred, remain to be identified.
Whether the lactacystin-induced aSYN aggregates seen here associate with the cell loss found in the SNpc and PPTg (and possibly other areas) and if they correlate with the severity of functional deficits shown by the rats, which mimic to a large extent the changes seen in the PPN of clinical PD cases, remains open to further investigations. However, a report by Gomez-Tortosa et al. (1999) , which showed that the small number of cortical Lewy bodies relative to the total neuron count does not correlate with the extent of cognitive impairment, suggest that a loss of function of still-existing nerve cells and not nerve cell loss itself is responsible for the clinical symptoms in PD. It has been shown that the majority of aSYN aggregates are located at presynaptic terminals. Intraneuronal Lewy bodies then form due to axonal retrograde transport of small, presynaptic aSYN aggregates (McNaught et al. 2002) . This is suggestive of a severe pathological impact on synaptic function and thus that presynaptic aSYN aggregation interferes with neurotransmitter release (Kramer and SchulzSchaeffer 2007) . In post-mortem brains of PD patients, decreased dendritic length, loss of dendritic spines and several types of dendritic varicosities were also described in neurons of the locus ceruleus and SN, whereas presynapses were relatively preserved, suggestive of a neurotransmitter deprivation (Patt and Gerhard 1993; Patt et al. 1991) . Related to this, in vivo imaging of synaptic functions of the CNS found compelling evidence for presynaptic neurotransmitter deficiencies in PD (Nikolaus et al. 2009 ).
Inflammation, comprising microglial activation, astrogliosis and lymphocytic infiltration, is regarded as another prominent feature affecting the SNpc of PD patients (Hirsch and Hunot 2009) and several animal models of PD (Kurkowska-Jastrzebska et al. 1999; Marinova-Mutafchieva et al. 2009 ). However, whether microglial activation promotes cell survival, possibly through glutamate uptake (Nakajima et al. 2008) , production of neurotrophic factors (Batchelor et al. 1999 ) and phagocytic removal of dead or dying neurons (Neumann et al. 2006) , or if activated microglia fulfil a cytotoxic role by triggering signalling cascades that release proinflammatory cytokines that contributes to neuronal death (reviewed in Nagatsu and Sawada 2005), remains unclear.
In OX-42-ir PPTg sections, which revealed all microglia across different stages of activation, the present work characterised the morphological alterations and immunophenotypic characteristics of microglia cells in the lactacystin rat model of PD. Specifically, in the PPTg on the ipsilateral side of toxin-lesioned rats, we detected marked upregulation of OX-42-ir fully activated microglia, presenting with a prominent phagocytic phenotype, characterised by thickening of ramifications and cell bodies, as well as acquiring a rounded amoeboid shape. In relation to the significant decrease seen in the number of non-ChAT NeuN-ir neuronal cell bodies at this time-point following the nigral lesion, it is plausible that activated microglia targeted degenerating neurons through the process of neuronophagia, in which phagocytes engulf dying neurons by adhering to axons, dendrites and the neuronal soma of degenerating neurons. Therefore, the data provide compelling evidence that a high degree of activated microglia associates directly with the cell loss seen and therefore participate in the neurodegenerative process.
The OX-6 antibody serves as a marker of activated microglial by recognising the major histocompatibility complex class II molecules (MHC-II) associated with induction of T-helper cells (O'Keefe et al. 2002) . On the other hand, immunoreactivity for the pan-microglial marker OX-42 aims to monitor activation of all brain resident monocytes or microglial cells by recognising the presence of leukocyte integrin complement receptor type 3 (CR3) on microglia (Graeber et al. 1989) . Our previous work reported a lack of activated OX-6-ir cells in the PPTg of lactacystin-lesioned rats (Pienaar et al. 2015a , b) using similar surgical parameters (i.e. stereotaxic coordinates, lactacystin dose and time-point post-lactacystin lesion for killing animals) as was used in the current study. It is feasible that by the terminal endpoint (5 weeks post-lesion), the OX-6-ir microglial response in the PPTg had completely abated, while this may have been present during the more acute period following neurotoxin exposure (i.e. at 1 week post-lesion). This is in line with studies reporting that microglia activation occurs within hours following CNS injury. This includes work by MarinovaMutafchieva et al. (2009) who reported that a single injection of 6-OHDA into the MFB of rats induced microglial activation in the SNpc at 1 day post injection, with the microglial response declining at 9 days post-lesion. In other work, Rodriguez-Pallares et al. (2007) reported microglial activation within the SNpc at 48 h following a single intrastriatal 6-OHDA injection in rats.
Unlike OX-42, OX-6 are not expressed in all microglia, while the increase in OX-42 immunoreactivity, as seen in the PPTg, is indicative of an upregulation of the CR3 receptor which, in turn, can lead to increased phagocytic activity (Morioka et al. 1992) . The majority of the observed OX-42-reactive microglial cells appeared hypertrophied and showed thick or stout processes, with dome rod-like and amoeboid microglia that were also observed.
Here we observed increased aSYN aggregates in close proximity to activated microglia in the lesioned rats, although complete aSYN-OX-42 overlap was not detected. A complete lack of such aggregates or activated microglial response was seen in sham-lesioned control rats. This signifies an important implication, namely that in the lactacystin rat model of PD, aggregated aSYN accumulation within PPTg neurons activate microglia and that this relationship was dependent on toxin dose exposure, since higher densities of aggregated microglia was seen in rostral PPTg segments that lay closest to the lesion site, with the high density of activated microglia which subsided at the most caudal end of the nucleus, where lower concentrations of the toxin had diffused to. It is therefore plausible that this relation between toxin dose, aSYN aggregation and microglial activation represents an important mechanism by which pathology progresses in this model of neurodegeneration. Our study reflects what has been reported by investigators studying other brain regions, namely that extracellular Lewy bodies, as well as nigral aggregates immunoreactive to aSYN, are often surrounded by activated microglia or inflammatory mediators (McGeer et al. 1988; Zhang et al. 2005) . However, the link between synuclein aggregation, microglial activation and neuronal death, as seen in this rat model of disease, can only be speculated upon in the current study. Future studies should aim to determine whether phagocytic microglia in the PPTg preferentially attach to cholinergic or to noncholinergic neurons and track OX-42 immunoreactivity in a time-dependent manner, relative to the progressive rate of cholinergic and non-cholinergic neuronal degeneration. In addition, cell models that model Lewy pathology (Luk et al. 2009 ) offer the possibility for dissecting whether protein aggregation per se, or the inflammatory process contribute most to the neurodegeneration, and in the case of both processes being implicated in neuronal death, the linear order in which they manifest.
Although the factors responsible for aSYN aggregation remain to be determined, the current study points towards plausible mechanism for the microglial activation observed in this rat model of PD, namely that the aggregated aSYN overexpression released by dying or dead PPTg neurons into the surrounding PPTg parenchyma, could instigate chronic inflammation aimed at removing released aSYN and thereby inadvertently reinforce neuronal degeneration. Although detailed mechanisms resulting in aSYN aggregation in familial or sporadic PD remain to be defined, understanding the role of aggregated aSYN in microglial activation is of major clinical relevance not only since microglial activation can maintain or even aggravate the disease process, but also since treatment with anti-inflammatory drugs could easily be initiated in PD patients with minimal risk for impeding the therapeutic effects of other disease-targeting therapies.
The presented data also imply that non-cholinergic PPTg neurons appear more resilient to lactacystin-induced cellular changes than cholinergic neurons. What renders cholinergic neurons more susceptible to aggregated aSYN-induced neurotoxicity remains incompletely understood at present. A factor that might play a role includes the neurotransmitter ACh and the oxidative stress associated with its metabolism; with oxidative stress that is a causal, or at least an ancillary, factor in the neuropathology of PD (Jenner 2003 ). Here we demonstrated significantly lower levels of the enzyme ChAT, for acetylating neuronal choline which, in turn, synthesises the neurotransmitter ACh, in remaining cholinergic neurons in the PPTg on the lesioned hemispheric side, compared to both the unlesioned hemispheric side and to either cerebral hemisphere in sham control rats. The decreased expression was observed along the rostral-caudal extent of the PPTg, but was particularly pronounced in PPTg sections located closest to the nigral lesion site. This result implies for lowered levels of the neurotransmitter ACh, which regulates aspects of cognitive processing, attention and sleep architecture (Van Dort et al. 2015) . Related to this, others have shown that PD patients that had received PPN-DBS show improved executive functions, working memory and sleep architecture (Alessandro et al. 2010) , suggesting that low-frequency DBS induces an increase in ACh in remaining cholinergic neurons of the PPN.
Therefore, opinion is growing that the pathophysiology of the neurodegenerative process cannot be explained by Lewy bodies, but that the clinical symptoms do indicate a degenerative process located at the presynapse, resulting in a neurotransmitter deficiency (reviewed in SchulzSchaeffer 2010). Moreover, neuropathological studies implicate a trans-synaptic spread of aSYN aggregate pathology (Braak et al. 2003) , since during the early stages of PD the pathological changes are restricted to brain regions that are involved in the later stages of disease pathology. Therefore, if presynaptic aSYN aggregation and not neuronal loss is the key mechanism underlying the neurodegenerative process, and the disease progresses via trans-synaptic spread, then a-synucleinopathies such as PD may become treatable in future, with studies focusing on the regeneration of synapses in PD-affected brains. This furthermore suggests that data on the stereological distribution pattern of aSYN aggregate within the PPTg in the current model of PD will be of limited use, as this will assume that Lewy body-like aggregates, rather than synaptic aggregates, is equivalent to the spread of pathology, including cell death.
Our understanding of the causes of PD, with the aim of optomising current treatment regimes and developing novel ones to improve the clinical management of PD will benefit greatly from more cell-specific approaches. Related to this, future work should aim to quantitatively determine which neuronal subgroup contained within the PPTg may be most vulnerable in the lactacystin as well as other toxininduced and genetic animal models of PD. In addition, our findings clearly demonstrate the transformation of microglia to antigen presenting cells expressing OX-42 at a relatively late stage following toxin inoculation to phagocytose PPTg neurons undergoing neuronal cell death. This result therefore suggests that blockading microglial activation or phagocytic activity might comprise useful targets for therapeutic intervention of the neurodegeneration affecting the PPN in PD cases. It cannot be excluded that activated accumulated microglia may have migrated from other brain regions undergoing neurodegeneration (Marella and Chabry 2004; Marinova-Mutafchieva et al. 2009 ) such as the SNpc, with this hypothesis that deserves further experimental exploration.
